Thursday, February 1, 2018

Nature Reviews Drug Discovery contents February 2018 Volume 17 Number 2 pp 79-150

If you are unable to see the message below, click here to view.
Nature Reviews Drug Discovery
 

Advertisement
Analyze Large and Small Molecule Inhibitors in a Single Homogeneous Assay

Want to analyze downstream cell signaling events impacted by both large and small molecule inhibitors in a single assay? Learn about a no-wash platform for screening antibodies and small molecule inhibitors, in this example used to characterize chemokine receptor inhibitors. 

Download Application Note
 
TABLE OF CONTENTS
 
February 2018 Volume 17 Number 2 Advertisement
 
Nature Reviews Drug Discovery cover
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38
In this issue
Comment
News and Analysis
Research Highlights
Perspectives
Reviews
Correspondence
 
Also this month
 Featured article:
Automating drug discovery
Gisbert Schneider

 
 
To mark the 100th anniversary of the 1918 influenza pandemic, Nature Reviews Microbiology presents a collection including Reviews and research articles from across Nature Research to showcase the latest advances in our understanding of influenza virus biology, evolution and adaptation, and advances in surveillance and drug and vaccine development.

Access the collection online.

 
Subscribe
 
Facebook
 
RSS
 
Recommend to library
 
Twitter
   
Advertisement
Discover a new path to your success via Human Data Science. IMS Health and Quintiles are now IQVIA™ - created to advance your pursuits of human science by unleashing the power of data science and human ingenuity. We are here to help you find solutions to drive healthcare forward.

Join the journey today.
 
Advertisement

BIOPHARMA DEALMAKERS
BioPharma DealmakersCompany Profiles and Partnering Opportunities

 
Advertisement
Nature Collection: Mitochondria and the heart

Nature Reviews Cardiology brings together a collection of articles from Nature Research journals highlighting the importance of mitochondria in the heart and the new opportunities for mitochondria-targeted therapies in cardiac diseases.

Access here >>

Produced with support from: 
Stealth BioTherapeutics 
 
Advertisement
nature.com webcasts

Springer Nature presents a custom webcast on: Untangling Neurodegenerative Diseases using Cryo-Electron Microscopy
Date: Wednesday, February 7, 2018

Register for the webcast and live Q&A session >>

Sponsored by: Thermo Fisher Scientific 
 
Comment: Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease
Robert N. Schuck, Michael Pacanowski, Janet Woodcock & Issam Zineh

p79 | doi:10.1038/nrd.2017.231
Numerous challenges arise when developing targeted therapies for diseases comprising low-frequency molecular subtypes. In this article, we describe a pragmatic, science-based regulatory policy for the development and approval of targeted therapies in such cases.
Full Text | PDF

 
 
NEWS AND ANALYSIS
 
Top
2017 FDA drug approvals
Asher Mullard

p81 | doi:10.1038/nrd.2018.4
The FDA approved 46 new drugs last year, the highest total in more than two decades.
PDF
 
NEWS IN BRIEF
Top product sales forecasts for 2018
Asher Mullard

p86 | doi:10.1038/nrd.2018.15
PDF
 
Pfizer exits neuroscience
Asher Mullard

p86 | doi:10.1038/nrd.2018.16
PDF
 
EMA recommended 35 new drugs in 2017
Asher Mullard

p86 | doi:10.1038/nrd.2018.17
PDF
 
BIOBUSINESS BRIEFS
Market watch: 2017 FDA drug approvals: number rebounds but average value slips
Mathias Baedeker, Michael Ringel, Valery Panier & Ulrik Schulze

p87 | doi:10.1038/nrd.2018.2
PDF
 
AN AUDIENCE WITH
Morgan Sheng
p88 | doi:10.1038/nrd.2017.271
PDF
 
FROM THE ANALYST'S COUCH
Biopharma deal-making in 2017
Amanda Micklus & Steven Muntner

p91 | doi:10.1038/nrd.2018.1
This article analyses merger and acquisition (M&A) activity and partnerships in the biopharma industry in 2017, highlighting trends and major deals.
PDF
 
RESEARCH HIGHLIGHTS
 
Top

Gene therapy: Reprogramming α-cells reverses diabetes
p93 | doi:10.1038/nrd.2018.7
PDF


Regenerative medicine: Cholesterol clearance restores remyelination
p94 | doi:10.1038/nrd.2018.12
PDF


Pharmacogenomics: Know your GPCR mutations (and target them right)
p94 | doi:10.1038/nrd.2018.13
PDF


Gene therapy: CRISPR therapies — making the grade not the cut
p95 | doi:10.1038/nrd.2018.3
PDF


Neurodegenerative diseases: Inflammasome protein seeds plaques in Alzheimer disease
p96 | doi:10.1038/nrd.2018.5
PDF


 


IN BRIEF

Cancer: Anticancer effects of alcohol abuse drug | Immunotherapy: Oncolytic virotherapy enables checkpoint blockade | Inflammation: Microbiome manipulation ameliorates colitis
PDF

Drug Discovery
JOBS of the week
Senior Scientist (Bioscience)
Sygnature Discovery
Post Doc Fellow – Structural Biology and Drug Discovery
The H. Lee Moffitt Cancer
Postdoctoral Fellow
University Health Network (Toronto)
Postdoc
University of Virginia
PhD Students and Postdoctoral Scientists
University Medical Center Freiburg
More Science jobs from
Drug Discovery
EVENT
5th NovAliX Conference - Biophysics in Drug Discovery 2018
13.07.18
Boston, USA
More science events from
Advertisement
Do you have a career question? 

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today!
 
 
PERSPECTIVES
 
Top
INNOVATION
Automating drug discovery
Gisbert Schneider

p97 | doi:10.1038/nrd.2017.232
Advances in areas such as microfluidics-assisted chemical synthesis and biological testing, as well as in artificial intelligence systems, are increasingly providing opportunities to introduce greater automation into the small-molecule drug discovery process. Schneider highlights approaches and technologies that seem poised to be implemented robustly by medicinal chemists in the near future and analyses the challenges for their more widespread application
Abstract | Full Text | PDF

 
 
 
REVIEWS
 
Top
Mechanistic enzymology in drug discovery: a fresh perspective
Geoffrey A. Holdgate, Thomas D. Meek & Rachel L. Grimley

p115 | doi:10.1038/nrd.2017.219
Understanding the role of enzymes in disease states and the implementation of strategies to modulate their activities for therapeutic benefit remains a key focus for drug discovery. Here, Holdgate and colleagues assess the benefits of conducting and applying high-quality mechanistic enzymology studies throughout a drug-discovery programme and assess the value of combining such knowledge with orthogonal biophysical methods.
Abstract | Full Text | PDF

 
Emptying the stores: lysosomal diseases and therapeutic strategies
Frances M. Platt

p133 | doi:10.1038/nrd.2017.214
Lysosomal storage disorders (LSDs) are rare, inherited metabolic disorders that result from defects in lysosomal function, for which treatment options are limited. Here, Platt provides an overview of LSDs, approved and potential therapeutic approaches and agents currently in development. The challenges associated with LSD diagnosis, drug development and treatment are discussed.
Abstract | Full Text | PDF

 
 
CORRESPONDENCE
 
Top
A dynamic map for learning, communicating, navigating and improving therapeutic development
John Wagner, Andrew M. Dahlem, Lynn D. Hudson, Sharon F. Terry, Russ B. Altman, C. Taylor Gilliland, Christopher DeFeo & Christopher P. Austin

p150 | doi:10.1038/nrd.2017.217
Full Text | PDF | Supplementary information
 
Corrigendum: 2017 FDA drug approvals
Asher Mullard

p150 | doi:10.1038/nrd.2018.18
Full Text | PDF
 
Advertisement
nature.com webcasts

Springer Nature presents a custom webcast on: Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology

Date: Tuesday, February 20, 2018 

Register for the webcast and live Q&A session 

Sponsored by: 
Mitra Biotech 
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: